logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Pharmaceutical Intermediates > BNP-32 (HUMAN) CAS 124584-08-3

BNP-32 (HUMAN) CAS 124584-08-3

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 124584-08-3

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:
CAS NO::
124584-08-3
Appearance::
Powder
Molecular Formula::
C143H244N50O42S4
Molecular Weight::
3464.04000
EINECS NO::
NA
MDL NO::
MFCD00133149
CAS NO::
124584-08-3
Appearance::
Powder
Molecular Formula::
C143H244N50O42S4
Molecular Weight::
3464.04000
EINECS NO::
NA
MDL NO::
MFCD00133149
BNP-32 (HUMAN) CAS 124584-08-3

Product Description:

Product Name: BNP-32 (HUMAN) CAS NO: 124584-08-3


Synonyms:

Nesiritide,Brain Natriuretic Peptide-32 human,BNP-32;

BNP-32 (human) hydrochloride;

Nesiritide [USAN:INN];


Chemical & Physical Properties:

Appearance: Powder

Assay :≥99.00%

Density: 1.52±0.1 g/cm3(Predicted)

Storage Temp.: −20℃

Water Solubility: Soluble in water at 1mg/ml

Index of Refraction: 1.679


Safety Information:

RTECS: EE1534000

WGK Germany: 3


Nesiritide (Natrecor) is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldoesterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation.

Neseritide was believed initially to be beneficial for acute decompensated congestive heart failure. It received approval from the United States' Food and Drug Administration for this purpose in 2001 after initial non-approval. In July 2011 the results of the largest study so far for nesiritide was published in The New England Journal of Medicine; it showed that nesiritide was not associated with a change in mortality or re-hospitalizations.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.